diabetic kidney disease

Peer-Reviewed PublicationMayo Clinic JACKSONVILLE, Fla. — Mayo Clinic researchers have identified a drug-and-supplement combination therapy that is capable of reducing the harmful effects of senescent cells – also known as “zombie cells” – in diabetic kidney disease. In eBioMedicine, a publication of The Lancet, the team reported that the combination of the cancer drug dasatanib and a naturally occurring substance […]

by National Taiwan University edited by Sadie Harley, reviewed by Robert Egan  Editors’ notes Comparative outcomes of finerenone versus spironolactone in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). Credit: National Taiwan University Researchers from National Taiwan University Hospital and collaborating institutions have demonstrated that finerenone, a new-generation nonsteroidal mineralocorticoid receptor antagonist (MRA), significantly reduces